Dry Age-Related Macular Degeneration Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Growing Aging Population
   3. Market Restraints
      1. Limited Treatment Options
      2. High Cost of R&D
   4. Market Opportunities
      1. Presence of Pipeline Drugs
   5. Market Trends
      1. Increased Emphasis on Personalized Medicine
      2. Integration of Digital Health Solutions
5. MARKET SEGMENTATION
   1. By Stages
      1. Early Age-Related Macular Degeneration
      2. Intermediate Age-Related Macular Degeneration
      3. Late Age-Related Macular Degeneration
   2. By Age Group
      1. Above 75 Years
      2. Above 60 Years
      3. Above 40 Years
   3. By Diagnosis and Treatment
      1. Treatment
      2. Diagnosis
   4. By Route of Administration
      1. Oral
      2. Injectable
   5. By End-User
      1. Hospitals and Clinics
      2. Diagnostic Centers
      3. Academic Research Institutes
   6. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Alimera Sciences Inc
      2. Allergan Plc
      3. Belite Bio Inc
      4. Bausch Health (Valeant Pharmaceuticals)
      5. Eyestem Research Pvt Ltd
      6. IVERIC Bio
      7. Kubota Vision Inc
      8. Ocumension Therapeutics (Shanghai) Co. Ltd.
      9. RXi Pharmaceuticals Inc. (Phio Pharmaceuticals Corp)
      10. Santen Pharmaceuticals Inc
      11. Stealth Biotherapeutics Corp
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Dry Age-Related Macular Degenerationmarket?

The global market of Dry Age-Related Macular Degeneration is projected to reach USD 20.9 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Dry Age-Related Macular Degenerationmarket?

The global Dry Age-Related Macular Degeneration market has an estimated annual growth rate of 8.2% .

Q.3. What are the recent trends of Dry Age-Related Macular Degenerationmarket?

Increased emphasis on personalized medicine and integration of digital health solutions are some of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Dry Age-Related Macular Degeneration?

The major companies profiled in this report include Alimera Sciences Inc, Allergan Plc, Belite Bio Inc, Bausch Health (Valeant Pharmaceuticals), Eyestem Research Pvt Ltd, IVERIC Bio, Kubota Vision Inc, Ocumension Therapeutics (Shanghai) Co. Ltd., RXi Pharmaceuticals Inc. (Phio Pharmaceuticals Corp), Santen Pharmaceuticals Inc, Stealth Biotherapeutics Corp, among others.

Q.5. Which region is estimated to held highest CAGR inDry Age-Related Macular Degenerationmarket?

North America is estimated to hold biggest share in the market for Dry Age-Related Macular Degeneration.